According to the man who has called nearly every bubble of the last 25 years, Bitcoin owners should get ready to pay back all the gains they've seen the last few months...

Click here to see Dan's full warning (and his potential solution)

Caroline Dorsa Biography and Net Worth

Director of Intellia Therapeutics

With a distinguished 30-year career as a top financial executive, Caroline Dorsa brings strong financial credentials and management expertise to Intellia’s Board of Directors, which she joined in 2015. In addition to her membership on Intellia’s board, she serves on the boards of directors for Biogen, Inc., where she chairs the audit committees, and Illumina, Inc. She is also on the board of trustees of several Goldman Sachs investment funds, such as the Goldman Sachs ETF Trust, the Goldman Sachs MLP and Energy Renaissance Fund and the Goldman Sachs MLP Income Opportunities Fund.

Caroline served as Executive Vice President and Chief Financial Officer of Public Service Enterprise Group, an integrated provider of regulated utility electric and gas distribution services, from April 2009 until her retirement in October 2015. Prior to that she served as Senior Vice President, Global Human Health, Strategy and Integration for Merck & Co. and Senior Vice President and CFO at Avaya, Inc., where she oversaw its leveraged buyout in 2007.

Caroline was honored in 2015 with the New Jersey Governor’s Jefferson Award for Public Service for her support of youth development in the state. She holds an MBA from Columbia University and earned her B.A. at Colgate University.

What is Caroline Dorsa's net worth?: The estimated net worth of Caroline Dorsa is at least $202,816.10 as of April 5th, 2021. Ms. Dorsa owns 12,910 shares of Intellia Therapeutics stock worth more than $202,816 as of November 14th. This net worth approximation does not reflect any other assets that Ms. Dorsa may own. Learn More about Caroline Dorsa's net worth.
How do I contact Caroline Dorsa?: The corporate mailing address for Ms. Dorsa and other Intellia Therapeutics executives is 40 Erie Street Suite 130, Cambridge MA, 02139. Intellia Therapeutics can also be reached via phone at (857) 285-6200 and via email at [email protected]. Learn More on Caroline Dorsa's contact information.
Has Caroline Dorsa been buying or selling shares of Intellia Therapeutics?: Caroline Dorsa has not been actively trading shares of Intellia Therapeutics within the last three months. Most recently, Caroline Dorsa sold 7,500 shares of the business's stock in a transaction on Monday, April 5th. The shares were sold at an average price of $82.19, for a transaction totalling $616,425.00. Following the completion of the sale, the director now directly owns 12,910 shares of the company's stock, valued at $1,061,072.90. Learn More on Caroline Dorsa's trading history.
Who are Intellia Therapeutics' active insiders?: Intellia Therapeutics' insider roster includes Eliana Clark (EVP), John Crowley (Director), Caroline Dorsa (Director), Jean-Francois Formela (Director), Glenn Goddard (CFO), David Lebwohl (EVP), John Leonard (CEO), Jose Rivera (EVP), Andrew Schiermeier (COO), and Laura Sepp-Lorenzino (EVP). Learn More on Intellia Therapeutics' active insiders.
Are insiders buying or selling shares of Intellia Therapeutics?: In the last year, insiders at the sold shares 7 times. They sold a total of 37,420 shares worth more than $1,085,489.31. The most recent insider tranaction occured on October, 2nd when CAO Michael P Dube sold 2,012 shares worth more than $38,248.12. Insiders at Intellia Therapeutics own 3.2% of the company. Learn More about insider trades at Intellia Therapeutics.
Information on this page was last updated on 10/2/2024.

Caroline Dorsa Insider Trading History at Intellia Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
4/5/2021	Sell	7,500	$82.19	$616,425.00	12,910

Caroline Dorsa Buying and Selling Activity at Intellia Therapeutics

Intellia Therapeutics Company Overview

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $15.71

$15.60

$16.28

50 Day Range

MA: $18.87

$14.22

$22.93

2 Week Range

Now: $15.71

$13.95

$34.87

Volume

705,634 shs

Average Volume

1,666,531 shs

Market Capitalization

$1.60 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.81

Post-Election Bitcoin Warning

From Stansberry Research | Ad